Oncopeptides AB (publ)

Oncopeptides AB (publ)

ONPPF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$56.69M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Oncopeptides AB (publ)Oncopeptides AB (publ)-2.8-4750%--20.3

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$56.69 Million
Enterprise Value$67.85 Million
Earnings per Share$-1.87
Beta-0.55
Outstanding Shares213,912,821

Return

Return on Equity4750.49%ROE
Return on Assets-160.07%
Return on Invested Capital-218.28%

Valuation & Multiples

P/E Ratio-2.81P/E Ratio
PEG27.04PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.27Price to Book Ratio
Enterprise Value to Revenue1.7
Enterprise Value to EBIT-0.24
Enterprise Value to Net Income-1
Total Debt to Enterprise1.74
Debt to Equity-20.26Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Oncopeptides AB (publ)

69 employees
CEO: Sofia Heigis

Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-dr...